RASI’S IN RECOMMENDED HIGHER TARGET DOSES MAY LOWER RISK OF DEATH AND KIDNEY FAILURE IN OCTOGENARIANS WITH HFREF

Abstract

Renin-angiotensin system inhibitors (RASIs) reduce the risk of death in patients with heart failure with reduced ejection fraction (HFrEF). National heart failure (HF) guidelines recommend that RASIs be used in higher target doses in patients with HFrEF. However, clinical trials of target vs.

The paper